1. A light-responsive liposomal agent for MRI contrast enhancement and monitoring of cargo delivery

   Reeßing, F., Stuart, M. C. A., Samplonius, D. F., Dierckx, R. A. J. O., Feringa, B. L., Helfrich, W. & Szymanski, W., 16-Sep-2019, In : Chemical communications (Cambridge, England). 55, 72, p. 10784-10787 4 p.

   Research output: Contribution to journal › Article › Academic › peer-review

2. Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade

   Koopmans, I., Hendriks, M. A. J. M., van Ginkel, R. J., Samplonius, D. F., Bremer, E. & Helfrich, W., 23-May-2019, In : Journal of Investigative Dermatology. 39 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition

   de Boer, H. R., Pool, M., Joosten, E., Everts, M., Samplonius, D. F., Helfrich, W., Groen, H. J. M., van Cooten, S., Fusetti, F., Fehrmann, R. S. N., de Vries, E. G. E. & van Vugt, M. A. T. M., 28-Feb-2019, In : ONCOGENE. 38, 9, p. 1477-1488 12 p.

   Research output: Contribution to journal › Article › Academic › peer-review

4. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

   Koopmans, I., Hendriks, D., Samplonius, D. F., van Ginkel, R. J., Heskamp, S., Wierstra, P. J., Bremer, E. & Helfrich, W., 2018, In : OncoImmunology. 7, 8, 11 p., 1466016.

   Research output: Contribution to journal › Article › Academic › peer-review

5. CD20-selective inhibition of CD47-SIRP alpha "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

   van Bommel, P. E., He, Y., Schepel, I., Hendriks, M. A. J. M., Wiersma, V. R., van Ginkel, R. J., van Meerten, T., Ammatuna, E., Huls, G., Samplonius, D. F., Helfrich, W. & Bremer, E., 2018, In : OncoImmunology. 7, 2, 8 p., e1386361.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (29) »